Week 01, 2018pdf, World Health Organization, SouthEast Asia Regional Office
Vol. 22, Week 01, 2018
Published 8 January 2018
Meetings/ Important events:
Regional Working Group Meeting on Immunization, New Delhi, India, 28-30 January 2018
Lessons from the Big Six- Closing the Immunity Gap for Measles Elimination and Rubella/ CRS control, New Delhi, India, 31 January-02
February 2018
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 8 January 2018)
Case classification (number)
Pending classification
Epidemiologicallyconfirmed
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
non-rubel l a
pop n
pop n
na ti ona l
ca s es per
l evel per
n
100,000
pop
100,000 pop n
Laboratory-confirmed
Discarded non-measles nonrubella cases
Rubel l a
Clinically-confirmed
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ecti on
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
ca s es wi th
%
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
on
mea s l es
s erum
i ni ti a ted s peci mens
ca s es
w/i n 48
col l ected
hours of
noti fi ca ti on
8,048
92
80
6,421
100
100
63
2,649
961
509
222
58
3,649
0
2.34
75
26.40
Bhutan
221
84
79
166
59
105
46
14
0
0
2
0
160
45
21.47
65
18.79
2.68
DPR Korea
105
100
100
105
100
100
99
0
0
0
0
0
105
0
0.42
0.00
0.00
Countries
Bangladesh
India 3
Indonesia
4
19,439
0
32
5,974
81
87
60
2,943
6,154
0
733
2,003
2,691
4,915
0.21
4,946
47
100
2,468
93
73
27
662
0
0
343
0
342
3,599
0.14
5
1.79
7.19
2.16
2.63
1.36
Maldives
63
97
100
63
100
100
70
1
0
0
1
0
59
2
17.26
60
2.93
2.93
Myanmar
1,683
41
89
1,459
99
100
94
1,046
189
63
3
0
349
33
0.68
14
25.24
0.06
Nepal
898
23
89
386
64
190
68
57
25
11
16
0
711
78
2.60
55
3.41
0.59
Sri Lanka
203
98
89
177
90
100
62
1
0
18
1
0
183
0
0.89
23
62.00
0.42
Thailand
2,864
29
88
2,390
58
95
59
1,426
14
458
24
0
849
93
1.31
29.26
0.37
127
100
99
119
100
72
52
0
0
0
3
0
120
4
9.90
38,597
32
60
19,728
87
94
59
8,799
7,343
1,059
1,348
2,061
9,218
8,769
0.49
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
4
38
A lso includes the cases fro m enhanced measles case-based surveillance.
0.00
2.48
9.22
1.83
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2016* (data as of 8 January 2018)
Case classification (number)
Bhutan
DPR Korea
India 3
3 732
100
100
92
619
354
96
165
0
Pending classification
Epidemiologicallyconfirmed
87
Discarded non-measles nonrubella cases
Laboratory-confirmed
94
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Clinically-confirmed
4 298
Rubel l a
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ecti on
Epidemiologicallyconfirmed
Bangladesh
Mea s l es
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
Countries
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
s erum
on
mea s l es
i ni ti a ted s peci mens
ca s es
col l ected
w/i n 48
hours of
noti fi ca ti on
3 064
0
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na ti ona l
ca s es per
l evel per
100,000 pop n
100,000 pop n
1.96
80
6.85
55
13.42
0.00
0.00
0.00
149
63
87
127
59
102
47
10
0
0
0
0
60
79
8.05
73
100
100
73
100
100
100
0
0
0
0
0
66
7
0.27
41 350
0
22
9 022
84
83
31
3 649
12 713
0
1 618
7 466
6 989
9 018
0.55
8 065
44
100
5 856
98
84
32
2 837
0
0
1 172
0
2 402
1 652
0.95
Maldives
11
100
100
11
100
0
0
0
0
0
0
0
11
0
3.22
Myanmar
587
0
86
503
100
99
97
194
59
21
10
0
303
0
0.59
1 079
13
82
1
100
0
137
102
31
22
0
772
15
Sri Lanka
339
63
86
291
88
100
68
64
0
48
1
0
226
Thailand
1 431
25
87
1 096
61
99
58
695
15
239
7
0
122
75
91
111
100
95
63
2
0
11
9
57 504
15
42
20 823
90
92
46
8 207
13 243
446
3 004
Indonesia
Nepal
4
5
Timor-Leste
SEAR
12.93
7.18
11.25
4.65
15
0.00
0.00
11
5.33
0.19
2.83
56
9.89
0.81
0
1.09
27
62.00
0.42
415
60
0.64
14.63
0.11
0
100
0
8.25
7 466
14 408
10 831
0.77
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
A lso includes the cases fro m enhanced measles case-based surveillance.
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
5
So me Lab data variables no t available.
3
1.06
46
10.73
7.43
11.74
5.61
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
Vol. 22,
Week 01, 2018
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2017-2018 (data as of 8 January 2018)
2017 (Onset)
2018 (Onset)
Surveillance Indicators
1
1
Non-Polio AFP Rate
% with 2 spec., at least
24 hrs apart, w/in 14
days
AFP Rate
Non-Polio AFP Rate
% with 2 spec., at least
24 hrs apart, w/in 14
days
% with any specimen
0
0
1,330
30
14
2.73
2.67
98
99
0.00
0.00
0
0
0
0
0
7
1
0
3.24
2.83
88
100
0.00
0.00
0
0
103
0
0
0
65
38
17
1.80
1.14
96
99
0.00
0.00
0
0
India
38,272
0
0
12
35,123 3,137 1,285
8.73
8.01
86
98
0.00
0.00
0
0
Indonesia
1,489
0
0
1
1,270
218
121
2.12
1.81
83
97
0.00
0.00
0
0
Maldives
6
0
0
0
4
2
0
6.34
4.23
67
100
0.00
0.00
0
0
Myanm ar
378
0
0
0
310
68
3
2.80
2.30
96
100
0.00
0.00
0
0
Nepal
341
0
0
0
326
15
2
3.93
3.76
99
100
0.00
0.00
0
0
Sri Lanka
69
0
0
0
67
2
1
1.27
1.23
84
99
0.00
0.00
0
0
Thailand
183
0
0
0
132
51
28
1.58
1.14
66
92
0.00
0.00
0
0
3
0
0
0
1
2
1
0.65
0.22
33
100
0.00
0.00
0
0
42,212
0
0
13
6.99
6.39
86
98
0.00
0.00
0
0
Bhutan
DPR Korea
Tim or-Leste
SEAR
38,635 3,564 1,472
0
0
0
0
0
>90 Days 3
Pending
Total
Compatible
4
Vaccine Derived
Poliovirus Cases
AFP Cases
Wild Poliovirus Cases
AFP Rate
0
8
Bangladesh
Pending
% with any specimen
>90 Days 3
1,360
Country
4
Total
Specim en
Discarded (Non-polio
AFP)
Case Classification
Compatible
Specim en
Vaccine Derived
Poliovirus Cases
2
Wild Poliovirus Cases
AFP Rates
Surveillance Indicators
Annualized
AFP Rates 2
AFP Cases
Case Classification
AFP
Discarded (Non-polio
AFP)
AFP
0
0
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2016-2017 (data as of 8 January 2018)
3
0
0
1
0
0
20
0
8
0
0
0
0
7
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
78
0
25
0
0
74
80
1
0
0
0
0
227
0
78
0
0
0
0
66
76
7
0
0
0
0
BJMC, Ahmedabad
India
0
258
Negative
1
0
NEV
0
0
Vaccine
mixture
NPEV by
PCR
0
1
Vaccine
0
0
Wild
0
0
VDPV
3
0
Wild
0
1
Vaccine
NEV
Negative
8
NIH, Bangkok
Vaccine
Wild
Vaccine
IPH, Dhaka
Bhutan
7
Days days
Wild
VDPV
Bangladesh
ITD Labs
Vaccine
mixture
NPEV by
PCR
Vaccine
Results
pending
Wild
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Vaccine
AFP cases
referred
for ITD
2017
Results
pending
Wild
Country of
Case
AFP cases
referred
for ITD
2016
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
7
days
NIV, Bengaluru
225
0
56
0
24
0
0
67
70
6
2
0
0
0
151
0
57
0
0
0
0
35
45
14
0
0
0
0
ERC, Mumbai
172
0
53
0
13
0
0
52
43
11
0
0
0
0
154
0
52
0
0
0
0
45
36
21
0
0
0
0
SGPGI, Lucknow
311
0
56
0
53
0
0
86
66
16
34
0
0
0
289
0
60
0
0
0
0
100
63
25
41
0
0
0
KIPM, Chennai
98
0
26
0
17
1
0
26
28
0
0
0
0
0
49
0
9
0
0
0
0
27
12
0
0
0
1
0
NCDC, Delhi
231
0
47
0
38
0
0
91
52
3
0
0
0
0
204
0
58
0
0
0
0
87
51
8
0
0
0
0
IoS, Kolkatta
113
0
26
0
18
0
0
35
33
0
1
0
0
0
173
0
54
0
0
0
0
39
57
18
3
0
2
0
CRI, Kasauli
35
0
5
0
7
0
0
11
12
0
0
0
0
0
22
0
11
0
0
0
0
6
5
0
0
0
0
0
India Total
1,443
0
347
0
195
1
0
442
384
37
37
0
0
0
1,269
0
379
0
0
0
0
405
345
93
44
0
3
0
Bio Farma, Bandung
18
0
9
0
3
0
0
1
5
0
0
0
0
0
2
0
0
0
0
0
0
2
0
0
0
0
0
0
NIHRD, Jakarta
12
0
4
0
0
0
0
5
3
0
0
0
0
0
2
0
0
0
0
0
0
0
2
0
0
0
0
0
PHL, Surabaya
13
0
2
0
4
0
0
4
3
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
Indonesia Total
43
0
15
0
7
0
0
10
11
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Myanm ar
NHL, Yangon
7
0
1
0
1
0
0
2
3
0
0
0
0
0
6
0
1
0
0
0
0
4
1
0
0
0
0
0
Nepal
NIH, Bangkok
6
0
2
0
2
0
0
1
1
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Sri Lanka
MRI, Colombo
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
4
0
0
0
0
0
0
2
2
0
0
0
0
0
5
0
2
0
0
0
0
3
0
0
0
0
0
0
1,513
0
368
0
206
1
0
459
404
37
37
1
0
0
1,310
0
390
0
0
0
0
425
355
93
44
0
3
0
Indonesia
TOTAL
Published 8 January 2018
Meetings/ Important events:
Regional Working Group Meeting on Immunization, New Delhi, India, 28-30 January 2018
Lessons from the Big Six- Closing the Immunity Gap for Measles Elimination and Rubella/ CRS control, New Delhi, India, 31 January-02
February 2018
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 8 January 2018)
Case classification (number)
Pending classification
Epidemiologicallyconfirmed
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
non-rubel l a
pop n
pop n
na ti ona l
ca s es per
l evel per
n
100,000
pop
100,000 pop n
Laboratory-confirmed
Discarded non-measles nonrubella cases
Rubel l a
Clinically-confirmed
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ecti on
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
ca s es wi th
%
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
on
mea s l es
s erum
i ni ti a ted s peci mens
ca s es
w/i n 48
col l ected
hours of
noti fi ca ti on
8,048
92
80
6,421
100
100
63
2,649
961
509
222
58
3,649
0
2.34
75
26.40
Bhutan
221
84
79
166
59
105
46
14
0
0
2
0
160
45
21.47
65
18.79
2.68
DPR Korea
105
100
100
105
100
100
99
0
0
0
0
0
105
0
0.42
0.00
0.00
Countries
Bangladesh
India 3
Indonesia
4
19,439
0
32
5,974
81
87
60
2,943
6,154
0
733
2,003
2,691
4,915
0.21
4,946
47
100
2,468
93
73
27
662
0
0
343
0
342
3,599
0.14
5
1.79
7.19
2.16
2.63
1.36
Maldives
63
97
100
63
100
100
70
1
0
0
1
0
59
2
17.26
60
2.93
2.93
Myanmar
1,683
41
89
1,459
99
100
94
1,046
189
63
3
0
349
33
0.68
14
25.24
0.06
Nepal
898
23
89
386
64
190
68
57
25
11
16
0
711
78
2.60
55
3.41
0.59
Sri Lanka
203
98
89
177
90
100
62
1
0
18
1
0
183
0
0.89
23
62.00
0.42
Thailand
2,864
29
88
2,390
58
95
59
1,426
14
458
24
0
849
93
1.31
29.26
0.37
127
100
99
119
100
72
52
0
0
0
3
0
120
4
9.90
38,597
32
60
19,728
87
94
59
8,799
7,343
1,059
1,348
2,061
9,218
8,769
0.49
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
4
38
A lso includes the cases fro m enhanced measles case-based surveillance.
0.00
2.48
9.22
1.83
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2016* (data as of 8 January 2018)
Case classification (number)
Bhutan
DPR Korea
India 3
3 732
100
100
92
619
354
96
165
0
Pending classification
Epidemiologicallyconfirmed
87
Discarded non-measles nonrubella cases
Laboratory-confirmed
94
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Clinically-confirmed
4 298
Rubel l a
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ecti on
Epidemiologicallyconfirmed
Bangladesh
Mea s l es
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
Countries
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves ti ga ti ca s es wi th
s erum
on
mea s l es
i ni ti a ted s peci mens
ca s es
col l ected
w/i n 48
hours of
noti fi ca ti on
3 064
0
Reporti ng
% di s tri cts
ra te of
reporti ng a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na ti ona l
ca s es per
l evel per
100,000 pop n
100,000 pop n
1.96
80
6.85
55
13.42
0.00
0.00
0.00
149
63
87
127
59
102
47
10
0
0
0
0
60
79
8.05
73
100
100
73
100
100
100
0
0
0
0
0
66
7
0.27
41 350
0
22
9 022
84
83
31
3 649
12 713
0
1 618
7 466
6 989
9 018
0.55
8 065
44
100
5 856
98
84
32
2 837
0
0
1 172
0
2 402
1 652
0.95
Maldives
11
100
100
11
100
0
0
0
0
0
0
0
11
0
3.22
Myanmar
587
0
86
503
100
99
97
194
59
21
10
0
303
0
0.59
1 079
13
82
1
100
0
137
102
31
22
0
772
15
Sri Lanka
339
63
86
291
88
100
68
64
0
48
1
0
226
Thailand
1 431
25
87
1 096
61
99
58
695
15
239
7
0
122
75
91
111
100
95
63
2
0
11
9
57 504
15
42
20 823
90
92
46
8 207
13 243
446
3 004
Indonesia
Nepal
4
5
Timor-Leste
SEAR
12.93
7.18
11.25
4.65
15
0.00
0.00
11
5.33
0.19
2.83
56
9.89
0.81
0
1.09
27
62.00
0.42
415
60
0.64
14.63
0.11
0
100
0
8.25
7 466
14 408
10 831
0.77
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
A lso includes the cases fro m enhanced measles case-based surveillance.
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
5
So me Lab data variables no t available.
3
1.06
46
10.73
7.43
11.74
5.61
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
Vol. 22,
Week 01, 2018
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2017-2018 (data as of 8 January 2018)
2017 (Onset)
2018 (Onset)
Surveillance Indicators
1
1
Non-Polio AFP Rate
% with 2 spec., at least
24 hrs apart, w/in 14
days
AFP Rate
Non-Polio AFP Rate
% with 2 spec., at least
24 hrs apart, w/in 14
days
% with any specimen
0
0
1,330
30
14
2.73
2.67
98
99
0.00
0.00
0
0
0
0
0
7
1
0
3.24
2.83
88
100
0.00
0.00
0
0
103
0
0
0
65
38
17
1.80
1.14
96
99
0.00
0.00
0
0
India
38,272
0
0
12
35,123 3,137 1,285
8.73
8.01
86
98
0.00
0.00
0
0
Indonesia
1,489
0
0
1
1,270
218
121
2.12
1.81
83
97
0.00
0.00
0
0
Maldives
6
0
0
0
4
2
0
6.34
4.23
67
100
0.00
0.00
0
0
Myanm ar
378
0
0
0
310
68
3
2.80
2.30
96
100
0.00
0.00
0
0
Nepal
341
0
0
0
326
15
2
3.93
3.76
99
100
0.00
0.00
0
0
Sri Lanka
69
0
0
0
67
2
1
1.27
1.23
84
99
0.00
0.00
0
0
Thailand
183
0
0
0
132
51
28
1.58
1.14
66
92
0.00
0.00
0
0
3
0
0
0
1
2
1
0.65
0.22
33
100
0.00
0.00
0
0
42,212
0
0
13
6.99
6.39
86
98
0.00
0.00
0
0
Bhutan
DPR Korea
Tim or-Leste
SEAR
38,635 3,564 1,472
0
0
0
0
0
>90 Days 3
Pending
Total
Compatible
4
Vaccine Derived
Poliovirus Cases
AFP Cases
Wild Poliovirus Cases
AFP Rate
0
8
Bangladesh
Pending
% with any specimen
>90 Days 3
1,360
Country
4
Total
Specim en
Discarded (Non-polio
AFP)
Case Classification
Compatible
Specim en
Vaccine Derived
Poliovirus Cases
2
Wild Poliovirus Cases
AFP Rates
Surveillance Indicators
Annualized
AFP Rates 2
AFP Cases
Case Classification
AFP
Discarded (Non-polio
AFP)
AFP
0
0
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2016-2017 (data as of 8 January 2018)
3
0
0
1
0
0
20
0
8
0
0
0
0
7
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
78
0
25
0
0
74
80
1
0
0
0
0
227
0
78
0
0
0
0
66
76
7
0
0
0
0
BJMC, Ahmedabad
India
0
258
Negative
1
0
NEV
0
0
Vaccine
mixture
NPEV by
PCR
0
1
Vaccine
0
0
Wild
0
0
VDPV
3
0
Wild
0
1
Vaccine
NEV
Negative
8
NIH, Bangkok
Vaccine
Wild
Vaccine
IPH, Dhaka
Bhutan
7
Days days
Wild
VDPV
Bangladesh
ITD Labs
Vaccine
mixture
NPEV by
PCR
Vaccine
Results
pending
Wild
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Vaccine
AFP cases
referred
for ITD
2017
Results
pending
Wild
Country of
Case
AFP cases
referred
for ITD
2016
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
7
days
NIV, Bengaluru
225
0
56
0
24
0
0
67
70
6
2
0
0
0
151
0
57
0
0
0
0
35
45
14
0
0
0
0
ERC, Mumbai
172
0
53
0
13
0
0
52
43
11
0
0
0
0
154
0
52
0
0
0
0
45
36
21
0
0
0
0
SGPGI, Lucknow
311
0
56
0
53
0
0
86
66
16
34
0
0
0
289
0
60
0
0
0
0
100
63
25
41
0
0
0
KIPM, Chennai
98
0
26
0
17
1
0
26
28
0
0
0
0
0
49
0
9
0
0
0
0
27
12
0
0
0
1
0
NCDC, Delhi
231
0
47
0
38
0
0
91
52
3
0
0
0
0
204
0
58
0
0
0
0
87
51
8
0
0
0
0
IoS, Kolkatta
113
0
26
0
18
0
0
35
33
0
1
0
0
0
173
0
54
0
0
0
0
39
57
18
3
0
2
0
CRI, Kasauli
35
0
5
0
7
0
0
11
12
0
0
0
0
0
22
0
11
0
0
0
0
6
5
0
0
0
0
0
India Total
1,443
0
347
0
195
1
0
442
384
37
37
0
0
0
1,269
0
379
0
0
0
0
405
345
93
44
0
3
0
Bio Farma, Bandung
18
0
9
0
3
0
0
1
5
0
0
0
0
0
2
0
0
0
0
0
0
2
0
0
0
0
0
0
NIHRD, Jakarta
12
0
4
0
0
0
0
5
3
0
0
0
0
0
2
0
0
0
0
0
0
0
2
0
0
0
0
0
PHL, Surabaya
13
0
2
0
4
0
0
4
3
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
Indonesia Total
43
0
15
0
7
0
0
10
11
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Myanm ar
NHL, Yangon
7
0
1
0
1
0
0
2
3
0
0
0
0
0
6
0
1
0
0
0
0
4
1
0
0
0
0
0
Nepal
NIH, Bangkok
6
0
2
0
2
0
0
1
1
0
0
0
0
0
5
0
0
0
0
0
0
3
2
0
0
0
0
0
Sri Lanka
MRI, Colombo
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
4
0
0
0
0
0
0
2
2
0
0
0
0
0
5
0
2
0
0
0
0
3
0
0
0
0
0
0
1,513
0
368
0
206
1
0
459
404
37
37
1
0
0
1,310
0
390
0
0
0
0
425
355
93
44
0
3
0
Indonesia
TOTAL